Market assessment of tuberculosis diagnostics in South Africa, 2012-2013

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 2, 2015, Pages 216-222

  Stevens, W S ^a,b,c   Schnippel, K ^b,d   Berrie, L ^a   Ginnard, J ^e   Perkins, M D ^f   Boehme, C C ^f   Jefferson, C ^g   Pantoja, A ^h   Chedore, P ⁱ   Denkinger, C M ⁱ   Pai, M ^i,j   Kik, S V ^i,j  

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d AURUM INSTITUTE   (South Africa)

^e Program Division Unitaid   (Switzerland)

^f FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^g UNITAID   (United States)

^h McGill University ^*  (Switzerland)

ⁱ MCGILL UNIVERSITY   (Canada)

^j MCGILL UNIVERSITY   (Canada)

more..

Author keywords

Costs; Diagnosis; Tests; Volume

Indexed keywords

ADENOSINE DEAMINASE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; ENZYME ANALYSIS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; INTERFERON GAMMA RELEASE ASSAY; MICROSCOPY; NUCLEIC ACID AMPLIFICATION; ORGANIZATION AND MANAGEMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PRIVATE HOSPITAL; SCALE UP; SOUTH AFRICA; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS RAPID TEST; DIAGNOSTIC TEST; DRUG EFFECTS; ECONOMICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; STATISTICS AND NUMERICAL DATA;

ANTITUBERCULAR AGENTS; DIAGNOSTIC TESTS, ROUTINE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; SOUTH AFRICA; SPUTUM; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84937116980     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0565     Document Type: Article

References (20)

1. World Health Organization. Global tuberculosis report, 2013: WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
2. World Health Organization. WHO monitoring of Xpert MTB/ RIF roll-out 2013. Geneva, Switzerland: WHO, 2013.
3. Kik S V, Denkinger C M, Casenghi M, Vadnais C, Pai M. Tuberculosis diagnostics: which target product profiles should be prioritised? Eur Respir J 2014; 44: 537-540.
4. Pai N P, Vadnais C, Denkinger C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low-and middle-income countries. PLOS Med 2012; 9: e1001306.
5. Pai M. Tuberculosis diagnostics: test developers' FAQs. Int J Tuberc Lung Dis 2013; 17: 570-571.
6. UNITAID. Tuberculosis: diagnostics technology and market landscape. 2nd ed. Geneva, Switzerland: UNITAID, 2013.
7. World Health Organization/Special Programme for Research and Training in Tropical Diseases/Foundation for Innovative New Diagnostics. Diagnostics for tuberculosis: global demand and market potential. Geneva, Switzerland: WHO, 2006.
8. Cobelens F, van den Hof S, Pai M, Squire S B, Ramsay A, Kimerling M E. Which new diagnostics for tuberculosis, and when? J Infect Dis 2012; 205 (Suppl 2): S191-S198.
9. Kik S V, Denkinger C M, Chedore P, Pai M. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J 2014; 43: 1793-1796.
10. TB Diagnostics Market Analysis Consortium. Market assessment of tuberculosis diagnostics in Brazil in 2012. PLOS ONE 2014 [In press].
11. Pai M. Diagnostics for tuberculosis: what test developers want to know. Expert Rev Mol Diagn 2013; 13: 311-314.
12. McIntyre D. What healthcare financing changes are needed to reach universal coverage in South Africa? S Afr Med J 2012; 102: 489-490.
13. World Health Organization. Fact sheet. Expanding and accelerating access to diagnostics for patients at risk of multidrug-resistant tuberculosis. Geneva, Switzerland: WHO, 2010: pp 1-2.
14. Motsoaledi A. Health budget vote policy speech presented at the National Assembly by the Minister of Health. Johannesburg, South Africa: Government of South Africa, 2011.
15. Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLOS ONE 2012; 7: e36966.
16. World Bank. World Bank data official exchange rate. Washington DC, USA: World Bank, 2012.
17. World Health Organization. Planning and budgeting for TB control activities. Geneva, Switzerland: WHO, 2010.
18. National Health Laboratory Service. State pricing catalogue 2011-2012. Pretoria, South Africa: Department of Health, 2011.
19. Shah M, Chihota V, Coetzee G, Churchyard G, Dorman S E. Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drugresistant tuberculosis in South Africa. BMC Infect Dis 2013; 13: 352.
20. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLOS MED 2011; 8: e1001120.